Target Corporation v. Golden State Ins. Co. Limited

CourtCalifornia Court of Appeal
DecidedOctober 10, 2019
DocketB279995
StatusPublished

This text of Target Corporation v. Golden State Ins. Co. Limited (Target Corporation v. Golden State Ins. Co. Limited) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Target Corporation v. Golden State Ins. Co. Limited, (Cal. Ct. App. 2019).

Opinion

Filed 10/10/19 CERTIFIED FOR PUBLICATION

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

SECOND APPELLATE DISTRICT

DIVISION SIX

TARGET CORPORATION, 2d Civil No. B279995 (Super. Ct. No. NC059999) Plaintiff and Appellant, (Los Angeles County)

v.

GOLDEN STATE INSURANCE COMPANY LIMITED et al.,

Defendants and Respondents.

This appeal involves complex issues in the interpretation of indemnification/defense clauses and additional insured endorsements. Target Corporation (retailer) appeals from the judgment entered in favor of respondents Golden State Insurance Company Limited (carrier) and its insured, McKesson Corporation (supplier), which had distributed a pharmaceutical product to retailer. Supplier’s contract with retailer included a clause requiring supplier to indemnify and defend retailer. Retailer was named as an additional insured on the policy that carrier had issued to supplier. A customer purchased from retailer the pharmaceutical product distributed by supplier. She had an adverse reaction to the product that resulted in serious bodily injury. Customer sued retailer, but supplier and carrier refused to defend it. Retailer brought the present action against supplier and carrier seeking to compel them to defend it. The trial court granted supplier’s and carrier’s motion for summary adjudication because customer’s lawsuit was based not on a defective product distributed by supplier, but on retailer’s alleged mislabeling of the product and failure to warn of possible adverse reactions to the product. We conclude that the indemnification/defense clause in supplier’s contract with retailer and the additional insured endorsement do not require supplier and carrier to defend retailer against customer’s lawsuit. Accordingly, we affirm. Factual and Procedural Background Supplier distributes prescription drugs, in bulk, to retailers. It does not manufacture drugs. Supplier and retailer entered into a Pharmaceutical Supply Agreement (the Agreement). The Agreement contained a broad indemnification clause requiring supplier to “indemnify, hold harmless, and defend [retailer] . . . against any and all actions [or] claims . . . relating to or arising out of . . . Products purchased by [retailer] from [supplier], . . . provided however, that the foregoing indemnity shall not apply to any claims . . . arising out of or due to the negligence or willful misconduct or omission of [retailer] . . . .” The Agreement said that “[supplier] shall obtain and maintain . . . commercial general liability insurance . . . , including products liability/completed operations . . . [and] coverage for contractual indemnification obligations.” The policy will “provide that [retailer] is included as an additional insured.”

2 The Agreement stated that it “shall be governed by and construed in accordance with the laws of the State of Minnesota.” Carrier issued a commercial general liability insurance policy designating supplier as the named insured and retailer as an additional insured. The additional insured endorsement provided that coverage applies “only with respect to ‘bodily injury’ or ‘property damage’ arising out of ‘your products’ [supplier’s products] . . . which are distributed or sold in the regular course of the vendor’s business [retailer’s business].” There is a key exception to the general coverage provision: Additional insured coverage does not apply to “[r]epackaging” of products or “[p]roducts which, after distribution or sale by you [supplier] have been labeled or relabeled.” The endorsement defined “[y]our products” as “[a]ny products of the named insured [supplier].” (Bold omitted; see infra pp. 8-9.) In August 2012 customer “filed products liability and professional negligence claims against [retailer and supplier] after developing a rare skin reaction . . . that she believes was caused by her ingestion of a prescription drug product . . . (a generic form of Septra DS [also known as Bactrim DS]) (hereinafter, the ‘Product’) she purchased at [retailer’s] pharmacy” in Northridge, California. Supplier had distributed the Product to retailer. Retailer “tendered the defense of the Underlying Action to [supplier],” which “accepted [retailer’s] tender.” Customer’s second amended complaint (customer’s complaint) consisted of six causes of action against retailer and supplier. The complaint alleged, “The bottle containing the Product supplied to [customer] instructed her to ‘Finish All Of This Medicine Unless Otherwise Directed By Your Doctor.’”

3 Customer contended that the label was “misleading and defective” because it did not contain “the FDA-approved” warning that the Product “should be discontinued at the first appearance of skin rash or any sign of adverse reaction.” (Bold and capitalization omitted.) Retailer and supplier allegedly “gave [customer] written instructions and literature regarding the description and use of the Product . . . which [she] relied upon, [and] which was inaccurate.” According to customer’s complaint, in October 2011 her “skin began to peel off all over her body. As a result, she was transferred to the burn unit at the University of Utah’s hospital where she remained in critical care for approximately 7 1/2 weeks after being diagnosed with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis . . . .” Retailer and supplier “failed . . . to provide adequate warnings to [customer] regarding the potential serious danger and proper use of the Product.” At customer’s request, in January 2014 her action against supplier, but not against retailer, was dismissed without prejudice pursuant to an agreement between customer and supplier. In June 2015 the action against supplier was dismissed with prejudice. In October 2014 retailer filed a motion for summary judgment. In opposition to the motion, customer stated: “Here, the evidence is that [retailer] did not use due care in labeling the medication.” [Customer] is not attempting to hold [retailer] liable on the basis that [it] dispensed a defectively designed drug.” “[Retailer] failed to properly warn [her] regarding the prescription for [the Product it] filled. [Retailer’s] failures were ones of both omission and commission. [It] not only omitted to provide warnings of side effects and adverse reactions that

4 should have been given, the instructions and warnings [it] did give were wrong. Following the instructions and not being properly warned, [customer] suffered the serious adverse reaction of having much of her skin burn off of her body.” In its January 2015 ruling denying retailer’s motion for summary judgment, the trial court said, “[Customer’s] basis for her claims is . . . failure to warn.” The court concluded: “The breach of warranty and strict liability claims survive because [retailer] designed and provided the labeling for the drug it dispensed, changing the FDA-approved labeling. The retailer thus was not providing the drug as it was given by the manufacturer. [Customer] claims that this constitutes a mislabeling, which is providing a product.” “The negligence causes of action survive because of the allegations that [retailer] negligently represented that the warnings and directions were adequate and ‘negligently failed to disclose . . . important safety and injury information’ about the drug.” In February 2015 carrier and supplier terminated their defense of retailer. In April 2015 retailer brought the present action for “the wrongful denial of a defense under contractual indemnity clauses by . . . [supplier] and under an insurance policy issued by . . . [carrier].” The complaint consists of three causes of action. The first cause of action is for declaratory relief.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Haarstad v. Graff
517 N.W.2d 582 (Supreme Court of Minnesota, 1994)
Wooddale Builders, Inc. v. Maryland Casualty Co.
722 N.W.2d 283 (Supreme Court of Minnesota, 2006)
Stiglich Construction, Inc. v. Larson
621 N.W.2d 801 (Court of Appeals of Minnesota, 2001)
Sdr Co., Inc. v. Federal Insurance
196 Cal. App. 3d 1433 (California Court of Appeal, 1987)
Meadowbrook, Inc. v. Tower Insurance Co.
559 N.W.2d 411 (Supreme Court of Minnesota, 1997)
Davis Ex Rel. Davis v. Outboard Marine Corp.
415 N.W.2d 719 (Court of Appeals of Minnesota, 1987)
Claudio v. Regents of University of Cal.
35 Cal. Rptr. 3d 837 (California Court of Appeal, 2005)
Jones v. Department of Corrections & Rehabilitation
62 Cal. Rptr. 3d 200 (California Court of Appeal, 2007)
Acceptance Insurance v. Syufy Enterprises
81 Cal. Rptr. 2d 557 (California Court of Appeal, 1999)
Aguilar v. Atlantic Richfield Co.
24 P.3d 493 (California Supreme Court, 2001)
Powerine Oil Co., Inc. v. Superior Court
118 P.3d 589 (California Supreme Court, 2005)
Martinez v. Combs
231 P.3d 259 (California Supreme Court, 2010)
Serri v. Santa Clara University
226 Cal. App. 4th 830 (California Court of Appeal, 2014)
Rice v. Downs
248 Cal. App. 4th 175 (California Court of Appeal, 2016)
Staffing Specifix, Inc. v. Tempworks Mgmt. Servs., Inc.
913 N.W.2d 687 (Supreme Court of Minnesota, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Target Corporation v. Golden State Ins. Co. Limited, Counsel Stack Legal Research, https://law.counselstack.com/opinion/target-corporation-v-golden-state-ins-co-limited-calctapp-2019.